Johns Hopkins University

- A phase 2 trial (randomized, placebo-controlled, and double-blinded) conducted in the U.K. investigated the safety and efficacy of inhaled nebulized interferon beta-1a (SNG001) for treatment of COVID-19.  101 COVID-19 patients (18 years and older) were randomly assigned to receive inhaled nebulized SNG001 or an inhaled placebo.  The WHO Ordinal Scale for Clinical Improvement (OSCI) was used to assess clinical conditions.  
- The COVID-19 patients who received inhaled nebulized SNG001 had a higher odds of exhibiting improvements in their clinical conditions and had a higher likelihood of recovering than the patients who received an inhaled placebo.  In addition, there were not any significant adverse effects reported from the inhaled nebulized SNG001, besides some reports of headache.  Further investigations should be conducted on the potential for using inhaled nebulized SNG001 as a treatment for COVID-19, given the results demonstrated in this study indicating that inhaled nebulized SNG001 can lead to higher likelihoods of clinical improvements as well as faster recoveries.  



Safety and Efficacy of Inhaled Nebulized Interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection

1. Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine. 2020;0(0). doi:10.1016/S2213-2600(20)30511-7


Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

Learn Before